F
Friedrich Grimminger
Researcher at University of Giessen
Publications - 431
Citations - 33019
Friedrich Grimminger is an academic researcher from University of Giessen. The author has contributed to research in topics: Pulmonary hypertension & Hypoxia (medical). The author has an hindex of 83, co-authored 402 publications receiving 30002 citations. Previous affiliations of Friedrich Grimminger include Goethe University Frankfurt.
Papers
More filters
Proceedings ArticleDOI
Increased Generation Of Reactive Oxygen Species In Pulmonary Arterial Smooth Muscle Cells In Monocrotaline-induced Pulmonary Arterial Hypertension In Rats
Florian Veit,Markus Roth,Bakytbek Egemnazarov,Hossain Ardeschir Ghofrani,Werner Seeger,Ralph T. Schermuly,Friedrich Grimminger,Norbert Weissmann +7 more
Proceedings ArticleDOI
A Highly Selective Endothelin-A Receptor Antagonist TBC3711 Reverses Monocrotaline Induced Pulmonary Hypertension
Djuro Kosanovic,Baktybek Kojonazarov,Bhola K. Dahal,Hossein Ardeschir Ghofrani,Norbert Weissmann,Friedrich Grimminger,Werner Seeger,Ralph T. Schermuly +7 more
Journal ArticleDOI
Microcirculatory dysfunction precedes changes in evoked potentials in endotoxin-induced sepsis syndrome in rats
Bernhard Rosengarten,M. Hecht,D. Auch,H. Ardeschir Ghofrani,Ralph Schermuly,Friedrich Grimminger,Manfred Kaps +6 more
Journal ArticleDOI
Nicotine promotes e-cigarette vapour-induced lung inflammation and structural alterations
Elsa Tadele Roxlau,Oleg Pak,Stefan Hadzic,Claudia F Garcia-Castro,Marija Gredic,Cheng-yu Wu,J Schäffer,Balachandar Selvakumar,Alexandra Pichl,Mariola Bednorz,Katharina Schäfer,Simone Kraut,Djuro Kosanovic,E M Zeidan,Baktybek Kojonazarov,Susanne Herold,Ievgen Strielkov,Andreas Guenther,Jochen Wilhelm,Mohamed M.A. Khalifa,Ashraf Taye,Ralf P. Brandes,Matthias Hecker,Friedrich Grimminger,Hossein Ardeschir Ghofrani,Ralph T. Schermuly,Werner Seeger,Natascha Sommer,Norbert Weissmann +28 more
TL;DR: In this paper , the effects of nicotine in e-cigarette vapour and its long-term effects on the airway, lung parenchyma and vasculature were investigated.
Proceedings ArticleDOI
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Marius M. Hoeper,Hossein Ardeschir Ghofrani,Hossein Ardeschir Ghofrani,Michael Halank,F. Joachim Meyer,Gerd Stähler,Jürgen Behr,Ralf Ewert,Monique Fletcher,Pablo Colorado,Sylvia Nikkho,Janethe de Oliveira Pena,Friedrich Grimminger +12 more
TL;DR: Riociguat is generally well tolerated in pts with PAH and CTEPH, and led to sustained improvements in 6MWD and WHO FC for up to 6 years.